ABBV Today - Aug 12: Downgrade Hits AbbVie
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
-
Letto da:
-
Di:
A proposito di questo titolo
So, here’s the scoop. AbbVie kind of coasted today, barely moving at all. It’s like when you’re just chilling on the couch, not really doing much. The stock was hovering around $249.83, so not a wild ride. But what’s interesting is that BTIG decided to downgrade Apogee Therapeutics, which is tied to AbbVie’s recent deal. That probably made some folks a bit uneasy, you know?
Now, onto the why. The market’s always got its ears perked up, and when news like a downgrade drops, people start hitting the sell button fast. It’s a chain reaction—when one piece of news hits, it can shake things up for other related stocks. Plus, there’s been chatter comparing AbbVie with CVS Health and Pfizer lately. Everyone’s trying to figure out who’s the better buy, and that’s always gonna cause some waves. It’s like a high school popularity contest, but for stocks.
Oh, and here’s a little tidbit for you—AbbVie is waiting on the FDA to review a new use for BOTOX. That could be a game-changer if it goes through, so keep an eye on that.
Alright, that’s a wrap for today! Just remember, this is all for fun and info, not financial advice. Stay curious, and I’ll catch you later!
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione